Whereas NSAID use was found to lower the risk of prostate cancer in carriers of a particular sequence variant of COX-2 and LTA, there was no association between NSAIDs and disease risk in men of alternate genotypes [10,15]. This evidence concerns the gene PTGS2 and Familial prostate cancer.